A cross-country core strategy comparison in China, Japan, Singapore and South Korea during the early COVID-19 pandemic.
Global Health
; 17(1): 22, 2021 02 22.
Article
in English
| MEDLINE | ID: covidwho-1094043
ABSTRACT
BACKGROUND:
The study aimed to analyze the effectiveness of COVID-19 strategies adopted by China, Japan, Singapore, and South Korea.METHODS:
We extracted publicly available data from various official websites, summarized the strategies implemented in these four countries, and assessed the effectiveness of the prevention and control measures adopted by these countries.RESULTS:
As of October 28, 2020, the growth of daily new confirmed cases has stabilized in China, Singapore, and South Korea. In Japan, the daily new confirmed cases increased sharply since it lifted a state of emergency, but case-fatality maintains at a lower level. The growth of total cases is near stagnant in China and Singapore, with a case-fatality of 5.39 and 0.05% respectively. The case-fatality rate between Japan and South Korea is identical at 1.76%, however, Japan's growth rate of cases has increased more rapidly than South Korea.CONCLUSION:
This study found that China, Japan, Singapore, and South Korea accessed the situation within their own borders and implemented different intervention strategies to curb the spread of COVID-19 and maintain lower rates of case-fatality. China, Singapore, and South Korea adopted the containment strategy, while Japan adopted the mitigation strategy. Although Japan's case-fatality maintained at a low level, daily new cases increased faster than the other three countries. This result indicated that a mitigation strategy could be inferior to a containment strategy.Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Cross-Cultural Comparison
/
Pandemics
/
COVID-19
Type of study:
Observational study
/
Randomized controlled trials
Limits:
Humans
Country/Region as subject:
Asia
Language:
English
Journal:
Global Health
Year:
2021
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS